Which has better earnings and valuation, INSM or CGON?

CG Oncology has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insmed $606.42M 44.79 -$1.28B -$4.11 N/A CG Oncology $4.04M 1,720.58 -$160.99M -$2.69 N/A

Is INSM or CGON more profitable?

Insmed has a net margin of -76.94% compared to CG Oncology's net margin of -3,602.68%. CG Oncology's return on equity of -25.20% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -76.94% -123.94% -44.30% CG Oncology -3,602.68% -25.20% -23.98%

Does the media favor INSM or CGON?

In the previous week, CG Oncology had 1 more articles in the media than Insmed. MarketBeat recorded 7 mentions for CG Oncology and 6 mentions for Insmed. CG Oncology's average media sentiment score of 1.05 beat Insmed's score of 0.83 indicating that CG Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CG Oncology 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ROIV or CGON?

In the previous week, Roivant Sciences had 6 more articles in the media than CG Oncology. MarketBeat recorded 13 mentions for Roivant Sciences and 7 mentions for CG Oncology. CG Oncology's average media sentiment score of 1.05 beat Roivant Sciences' score of 0.47 indicating that CG Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CG Oncology 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, INCY or CGON?

Incyte has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Incyte $5.14B 5.05 $1.29B $7.85 16.32 CG Oncology $4.04M 1,720.58 -$160.99M -$2.69 N/A

Is INCY or CGON more profitable?

Incyte has a net margin of 27.71% compared to CG Oncology's net margin of -3,602.68%. Incyte's return on equity of 29.93% beat CG Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Incyte 27.71% 29.93% 22.88% CG Oncology -3,602.68% -25.20% -23.98%

Does the media refer more to INCY or CGON?

In the previous week, Incyte had 33 more articles in the media than CG Oncology. MarketBeat recorded 40 mentions for Incyte and 7 mentions for CG Oncology. Incyte's average media sentiment score of 1.32 beat CG Oncology's score of 1.05 indicating that Incyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 29 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CG Oncology 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor UTHR or CGON?

In the previous week, United Therapeutics had 33 more articles in the media than CG Oncology. MarketBeat recorded 40 mentions for United Therapeutics and 7 mentions for CG Oncology. United Therapeutics' average media sentiment score of 1.37 beat CG Oncology's score of 1.05 indicating that United Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 30 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CG Oncology 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, CGON or GMAB?

Genmab A/S has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CG Oncology $4.04M 1,720.58 -$160.99M -$2.69 N/A Genmab A/S $3.72B 5.66 $963M $1.27 26.57

Is CGON or GMAB more profitable?

Genmab A/S has a net margin of 19.08% compared to CG Oncology's net margin of -3,602.68%. Genmab A/S's return on equity of 14.89% beat CG Oncology's return on equity. Company Net Margins Return on Equity Return on Assets CG Oncology -3,602.68% -25.20% -23.98% Genmab A/S 19.08% 14.89% 7.73%

Does the media refer more to CGON or GMAB?

In the previous week, CG Oncology had 2 more articles in the media than Genmab A/S. MarketBeat recorded 7 mentions for CG Oncology and 5 mentions for Genmab A/S. CG Oncology's average media sentiment score of 1.05 beat Genmab A/S's score of 0.62 indicating that CG Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genmab A/S 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

CG Oncology (CGON) Competitors

$78.42 -0.53 (-0.67%)

As of 04:00 PM Eastern

Compare

CGON vs. INSM, ROIV, INCY, UTHR, and GMAB

Should you buy CG Oncology stock or one of its competitors? CG Oncology's main competitors and comparable companies include Insmed (INSM), Roivant Sciences (ROIV), Incyte (INCY), United Therapeutics (UTHR), and Genmab A/S (GMAB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does CG Oncology compare to Insmed?

Insmed (NASDAQ:INSM) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

26.6% of CG Oncology shares are owned by institutional investors. 2.1% of Insmed shares are owned by insiders. Comparatively, 4.8% of CG Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Insmed has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market. Comparatively, CG Oncology has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market.

Insmed has a net margin of -76.94% compared to CG Oncology's net margin of -3,602.68%. CG Oncology's return on equity of -25.20% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-76.94%	-123.94%	-44.30%
CG Oncology	-3,602.68%	-25.20%	-23.98%

CG Oncology has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	44.79	-$1.28B	-$4.11	N/A
CG Oncology	$4.04M	1,720.58	-$160.99M	-$2.69	N/A

Insmed currently has a consensus target price of $205.52, indicating a potential upside of 65.22%. CG Oncology has a consensus target price of $83.18, indicating a potential upside of 6.07%. Given Insmed's stronger consensus rating and higher probable upside, equities analysts clearly believe Insmed is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, CG Oncology had 1 more articles in the media than Insmed. MarketBeat recorded 7 mentions for CG Oncology and 6 mentions for Insmed. CG Oncology's average media sentiment score of 1.05 beat Insmed's score of 0.83 indicating that CG Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CG Oncology	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

CG Oncology beats Insmed on 10 of the 17 factors compared between the two stocks.

How does CG Oncology compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Roivant Sciences has a net margin of -3,534.96% compared to CG Oncology's net margin of -3,602.68%. Roivant Sciences' return on equity of -22.94% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
CG Oncology	-3,602.68%	-25.20%	-23.98%

Roivant Sciences presently has a consensus target price of $35.14, suggesting a potential downside of 4.39%. CG Oncology has a consensus target price of $83.18, suggesting a potential upside of 6.07%. Given CG Oncology's higher probable upside, analysts clearly believe CG Oncology is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 26.6% of CG Oncology shares are owned by institutional investors. 8.8% of Roivant Sciences shares are owned by insiders. Comparatively, 4.8% of CG Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Roivant Sciences has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market. Comparatively, CG Oncology has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market.

In the previous week, Roivant Sciences had 6 more articles in the media than CG Oncology. MarketBeat recorded 13 mentions for Roivant Sciences and 7 mentions for CG Oncology. CG Oncology's average media sentiment score of 1.05 beat Roivant Sciences' score of 0.47 indicating that CG Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CG Oncology	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CG Oncology has lower revenue, but higher earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,213.71	-$299.77M	-$0.53	N/A
CG Oncology	$4.04M	1,720.58	-$160.99M	-$2.69	N/A

Summary

Roivant Sciences beats CG Oncology on 12 of the 17 factors compared between the two stocks.

How does CG Oncology compare to Incyte?

Incyte (NASDAQ:INCY) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

Incyte has a net margin of 27.71% compared to CG Oncology's net margin of -3,602.68%. Incyte's return on equity of 29.93% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	27.71%	29.93%	22.88%
CG Oncology	-3,602.68%	-25.20%	-23.98%

In the previous week, Incyte had 33 more articles in the media than CG Oncology. MarketBeat recorded 40 mentions for Incyte and 7 mentions for CG Oncology. Incyte's average media sentiment score of 1.32 beat CG Oncology's score of 1.05 indicating that Incyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	29 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CG Oncology	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Incyte has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	5.05	$1.29B	$7.85	16.32
CG Oncology	$4.04M	1,720.58	-$160.99M	-$2.69	N/A

Incyte currently has a consensus price target of $123.10, indicating a potential downside of 3.92%. CG Oncology has a consensus price target of $83.18, indicating a potential upside of 6.07%. Given CG Oncology's stronger consensus rating and higher probable upside, analysts clearly believe CG Oncology is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	0 Sell rating(s)	12 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.56
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

97.0% of Incyte shares are held by institutional investors. Comparatively, 26.6% of CG Oncology shares are held by institutional investors. 16.2% of Incyte shares are held by company insiders. Comparatively, 4.8% of CG Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Incyte has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, CG Oncology has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market.

Summary

Incyte beats CG Oncology on 14 of the 17 factors compared between the two stocks.

How does CG Oncology compare to United Therapeutics?

United Therapeutics (NASDAQ:UTHR) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends.

94.1% of United Therapeutics shares are held by institutional investors. Comparatively, 26.6% of CG Oncology shares are held by institutional investors. 8.6% of United Therapeutics shares are held by company insiders. Comparatively, 4.8% of CG Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

United Therapeutics has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.15B	7.03	$1.33B	$27.95	18.49
CG Oncology	$4.04M	1,720.58	-$160.99M	-$2.69	N/A

United Therapeutics has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market. Comparatively, CG Oncology has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market.

United Therapeutics presently has a consensus price target of $646.00, suggesting a potential upside of 25.03%. CG Oncology has a consensus price target of $83.18, suggesting a potential upside of 6.07%. Given United Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe United Therapeutics is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

United Therapeutics has a net margin of 41.56% compared to CG Oncology's net margin of -3,602.68%. United Therapeutics' return on equity of 20.18% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	41.56%	20.18%	17.98%
CG Oncology	-3,602.68%	-25.20%	-23.98%

In the previous week, United Therapeutics had 33 more articles in the media than CG Oncology. MarketBeat recorded 40 mentions for United Therapeutics and 7 mentions for CG Oncology. United Therapeutics' average media sentiment score of 1.37 beat CG Oncology's score of 1.05 indicating that United Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	30 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CG Oncology	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

United Therapeutics beats CG Oncology on 14 of the 15 factors compared between the two stocks.

How does CG Oncology compare to Genmab A/S?

CG Oncology (NASDAQ:CGON) and Genmab A/S (NASDAQ:GMAB) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

CG Oncology currently has a consensus price target of $83.18, suggesting a potential upside of 6.07%. Genmab A/S has a consensus price target of $39.50, suggesting a potential upside of 17.04%. Given Genmab A/S's stronger consensus rating and higher probable upside, analysts plainly believe Genmab A/S is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85

26.6% of CG Oncology shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 4.8% of CG Oncology shares are held by company insiders. Comparatively, 1.5% of Genmab A/S shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, CG Oncology had 2 more articles in the media than Genmab A/S. MarketBeat recorded 7 mentions for CG Oncology and 5 mentions for Genmab A/S. CG Oncology's average media sentiment score of 1.05 beat Genmab A/S's score of 0.62 indicating that CG Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Genmab A/S has a net margin of 19.08% compared to CG Oncology's net margin of -3,602.68%. Genmab A/S's return on equity of 14.89% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	-3,602.68%	-25.20%	-23.98%
Genmab A/S	19.08%	14.89%	7.73%

Genmab A/S has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,720.58	-$160.99M	-$2.69	N/A
Genmab A/S	$3.72B	5.66	$963M	$1.27	26.57

CG Oncology has a beta of 0.23, meaning that its share price is 77% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market.

Summary

Genmab A/S beats CG Oncology on 11 of the 17 factors compared between the two stocks.

Get CG Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CGON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CGON vs. The Competition

Export

Metric	CG Oncology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.95B	$4.03B	$7.30B	$12.78B
Dividend Yield	N/A	3.63%	2.53%	10.79%
P/E Ratio	-29.15	11.61	272.55	24.16
Price / Sales	1,720.58	1,369.12	627.50	98.47
Price / Cash	N/A	103.64	78.57	53.12
Price / Book	6.75	16.90	13.15	6.23
Net Income	-$160.99M	-$22.76M	$3.47B	$348.07M
7 Day Performance	-2.80%	1.62%	1.45%	0.72%
1 Month Performance	13.13%	11.88%	8.72%	4.89%
1 Year Performance	190.12%	57.32%	26.12%	16.95%

CG Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CGON CG Oncology	2.8326 of 5 stars	$78.42 -0.7%	$83.18 +6.1%	+210.6%	$6.95B	$4.04M	N/A	61	Positive News
INSM Insmed	3.419 of 5 stars	$123.89 -0.1%	$205.52 +65.9%	-3.5%	$27.06B	$1.14B	N/A	1,664
ROIV Roivant Sciences	1.9702 of 5 stars	$36.47 +0.3%	$35.14 -3.7%	+213.3%	$26.34B	$7.53M	N/A	860	Analyst Forecast
INCY Incyte	3.8841 of 5 stars	$129.72 +1.4%	$123.10 -5.1%	+53.0%	$26.29B	$5.14B	16.52	2,844	Positive News Analyst Upgrade
UTHR United Therapeutics	4.6872 of 5 stars	$518.53 +1.1%	$646.00 +24.6%	+69.8%	$22.24B	$3.18B	18.55	1,400	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CGON) was last updated on 8/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CG Oncology (CGON) Competitors

CGON vs. INSM, ROIV, INCY, UTHR, and GMAB

How does CG Oncology compare to Insmed?

Summary

How does CG Oncology compare to Roivant Sciences?

Summary

How does CG Oncology compare to Incyte?

Summary

How does CG Oncology compare to United Therapeutics?

Summary

How does CG Oncology compare to Genmab A/S?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGON vs. The Competition

CG Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CG Oncology (CGON) Competitors

CGON vs. INSM, ROIV, INCY, UTHR, and GMAB

How does CG Oncology compare to Insmed?

Do institutionals and insiders believe in INSM or CGON?

Which has more volatility and risk, INSM or CGON?

Is INSM or CGON more profitable?

Which has better earnings and valuation, INSM or CGON?

Do analysts rate INSM or CGON?

Does the media favor INSM or CGON?

Summary

How does CG Oncology compare to Roivant Sciences?

Is ROIV or CGON more profitable?

Do analysts recommend ROIV or CGON?

Do institutionals & insiders hold more shares of ROIV or CGON?

Which has more volatility & risk, ROIV or CGON?

Does the media favor ROIV or CGON?

Which has preferable earnings and valuation, ROIV or CGON?

Summary

How does CG Oncology compare to Incyte?

Is INCY or CGON more profitable?

Does the media refer more to INCY or CGON?

Which has stronger earnings and valuation, INCY or CGON?

Do analysts recommend INCY or CGON?

Do institutionals and insiders have more ownership in INCY or CGON?

Which has more volatility and risk, INCY or CGON?

Summary

How does CG Oncology compare to United Therapeutics?

Do institutionals and insiders believe in UTHR or CGON?

Which has higher valuation and earnings, UTHR or CGON?

Which has more volatility and risk, UTHR or CGON?

Do analysts rate UTHR or CGON?

Is UTHR or CGON more profitable?

Does the media favor UTHR or CGON?

Summary

How does CG Oncology compare to Genmab A/S?

Do analysts recommend CGON or GMAB?

Do insiders and institutionals have more ownership in CGON or GMAB?

Does the media refer more to CGON or GMAB?

Is CGON or GMAB more profitable?

Which has higher valuation & earnings, CGON or GMAB?

Which has more risk & volatility, CGON or GMAB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGON vs. The Competition

CG Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools